bioRxivBioengineeringPreprint
Non-viral Intron Knockins Enable Simplified and Flexible Targeting of Endogenous Genes
T. L. Roth, J. Lu, A. McClellan, O. Takacsi-Nagy, A. L. Satpathy
Abstract
Targeting new genetic material to endogenous genes has opened diverse therapeutic and research applications, but current exon-based targeting methods have limited integration sites and are compatible only with complex or harsh selection methods. We present non-viral intron targeting, integrating large synthetic exons into endogenous introns to increase targeting flexibility and simplify selection of successfully edited cells. Engineered control of large synthetic exons splicing behavior further generalizes cell and gene therapy applications of non-viral intron knockins.
- research focus: gene regulatory network inference
- research focus: clustering
- research focus: cell type annotation
- approach: experimental assay
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Endogenous intronic RNA tightly controls Cas9/CRISPR-mediated gene editing in human cells
Andre Lemos Carneiro, João T. Proença, … Vasco M. Barreto·bioRxiv·May 23, 2026
- Scalable tagging of endogenous genes by homology-independent intron targeting
Y. V. Serebrenik, S. E. Sansbury, … O. H. Shalem·bioRxiv·Sep 10, 2018
- Splicing-guaranteed artificial introns enable efficient homology-directed repair at internal exons and streamlined cell engineering
Shang Wang, Xianteng Wang, … Weiren Huang·bioRxiv·Oct 16, 2026
- An exosome-based gene delivery platform for cell-specific CRISPR/Cas9 genome editing
Sunil Dubey, Zhe Chen, … Fatemeh Momen‐Heravi·bioRxiv·Jun 9, 2023
- Targetron-assisted delivery of exogenous DNA sequences into Pseudomonas putida through CRISPR-aided counterselection
Elena Velázquez, Yamal Al‐Ramahi, … Vı́ctor de Lorenzo·ACS Synthetic BiologyPeer-reviewed·Oct 2, 2021
- Viral delivery of compact CRISPR-Cas12f for in vivo gene editing applications
Allison M. Sharrar, Zuriah A. Meacham, … Michael W. Schelle·bioRxiv·Feb 6, 2024